- Home
- ADV vs INBX Comparison
ADV vs INBX Comparison
Compare ADV & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- INBX
- Stock Information
- Founded
- ADV 1987
- INBX 2010
- Country
- ADV United States
- INBX United States
- Employees
- ADV N/A
- INBX N/A
- Industry
- ADV Business Services
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ADV Consumer Discretionary
- INBX Health Care
- Exchange
- ADV Nasdaq
- INBX Nasdaq
- Market Cap
- ADV 495.4M
- INBX 430.2M
- IPO Year
- ADV N/A
- INBX 2020
- Fundamental
- Price
- ADV $1.49
- INBX $58.02
- Analyst Decision
- ADV Strong Buy
- INBX Hold
- Analyst Count
- ADV 1
- INBX 2
- Target Price
- ADV $2.50
- INBX N/A
- AVG Volume (30 Days)
- ADV 411.6K
- INBX 525.4K
- Earning Date
- ADV 11-06-2025
- INBX 11-13-2025
- Dividend Yield
- ADV N/A
- INBX N/A
- EPS Growth
- ADV N/A
- INBX N/A
- EPS
- ADV N/A
- INBX N/A
- Revenue
- ADV $3,527,054,000.00
- INBX $1,400,000.00
- Revenue This Year
- ADV N/A
- INBX $563.00
- Revenue Next Year
- ADV $0.67
- INBX $230.77
- P/E Ratio
- ADV N/A
- INBX N/A
- Revenue Growth
- ADV N/A
- INBX N/A
- 52 Week Low
- ADV $1.04
- INBX $10.81
- 52 Week High
- ADV $4.04
- INBX $60.20
- Technical
- Relative Strength Index (RSI)
- ADV 45.84
- INBX 77.36
- Support Level
- ADV $1.40
- INBX $28.16
- Resistance Level
- ADV $1.49
- INBX $39.27
- Average True Range (ATR)
- ADV 0.09
- INBX 3.80
- MACD
- ADV 0.01
- INBX 0.87
- Stochastic Oscillator
- ADV 60.87
- INBX 98.40
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.